Jan. 10, 2013 ? A drug that protects a kidneys of patients with ongoing kidney illness does not seem to yield a same advantage to kidney transplant recipients, according to a investigate appearing in an arriving emanate of a Journal of a American Society of Nephrology (JASN).
Immunosuppressants assistance lengthen a duty of transplanted organs, though therapies that aim non-immunological repairs to these viscera — such as towering blood vigour and hankie scarring (or fibrosis) — have not been studied.
Angiotensin II blockade, that causes blood vessels to dilate, can delayed a course of kidney illness in people but kidney transplants. Hassan Ibrahim, MD (University of Minnesota) and his colleagues set out to exam a plan in transplant recipients. “To a believe this is a initial randomized placebo-controlled hearing of angiotensin II besiege in these patients,†pronounced Dr. Ibrahim.
The investigators reserved 153 kidney transplant recipients to accept a angiotensin II receptor blocker losartan or remedy within 3 months of transplantation, stability diagnosis for 5 years.
“Contrary to what has been celebrated in local kidney disease, angiotensin II besiege did not denote a statistically poignant advantage in alleviation fibrosis or depot kidney disaster from serious fibrosis. Nevertheless, angiotensin II besiege was protected and well-tolerated,†pronounced Dr. Ibrahim. He remarkable that a identical hearing is ongoing in Canada.
The commentary yield profitable information for destiny studies of non-immunological therapies for kidney transplant recipients.
Study co-authors embody Scott Jackson, MS, Jeffrey Connaire, MD, Arthur Matas, MD, Arthur Ney, MD, Ann West, RN, Nicole Lentsch, RN, Jensina Ericksen, Jenny Bodner, RN, Bertram Kasiske, MD, FACP (Hennepin County Medical Center); Behzad Najafian, MD (University of Washington); and Michael Mauer, MD (University of Minnesota).
Other amicable bookmarking and pity tools:
Story Source:
The above story is reprinted from materials supposing by American Society of Nephrology, around Newswise.
Note: Materials might be edited for calm and length. For serve information, greatfully hit a source cited above.
Journal Reference:
- Hassan N. Ibrahim, Scott Jackson, Jeffery Connaire, Arthur Matas, Arthur Ney, Behzad Najafian, Ann West, Nicole Lentsch, Jensina Ericksen, Jenny Bodner, Bertram Kasiske and Michael Mauer. Angiotensin II Blockade in Kidney Transplant Recipients. JASN, Jan 10, 2013 DOI: 10.1681/2012080777
Note: If no author is given, a source is cited instead.
Disclaimer: This essay is not dictated to yield medical advice, diagnosis or treatment. Views voiced here do not indispensably simulate those of ScienceDaily or the staff.
